Navigation Links
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
Date:6/2/2008

Data Show Encouraging Results for a Potential New Front-Line Treatment

Approach in AML

CAMBRIDGE, Mass., June 2 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) reported preliminary data today from a fully-enrolled pivotal, phase 2 study examining the safety and effectiveness of Clolar(R) (clofarabine) as a single agent in previously untreated, older adult patients with acute myelogenous leukemia (AML) who are unlikely to benefit from conventional "7+3" anthracycline plus cytarabine-based induction chemotherapy.

Results from the CLASSIC-II clinical trial show that patients with unfavorable prognostic factors who received single agent clofarabine exhibited a 45 percent overall remission rate based on investigator assessment, with manageable treatment-related side effects. Importantly, the 30 day all-cause mortality, one of the secondary endpoints in this study, was only 9.6 percent, which compares favorably to existing treatment options. Data from the study were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

"The therapeutic outcomes for older AML patients have not improved in the past thirty years," stated Mark J. Enyedy, president of Genzyme Oncology, a business unit of Genzyme Corporation. "These data highlight the potential of clofarabine to become an innovative and much needed treatment option for these patients. We look forward to submitting a supplemental new drug application in the United States later this year to expand the current product label into front-line therapy for adult AML and to make a similar filing in Europe around this same time."

Study Results

As reported at ASCO, investigator-assessed response da
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... LAKE, N.J. and STAMFORD, Conn. ... U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue ... a worldwide collaboration agreement for the development and commercialization ... dual orexin receptor antagonist entering Phase III clinical development ... the terms of the agreement, Eisai and Purdue Pharma ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited (ASX:BNO, ... development of innovative therapeutics for the treatment of diseases ... announced that its BNC101 IND submission has passed review ... plans to initiate a Phase 1 clinical trial in ... metastatic pancreatic cancer prior to 31 December 2015. ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/wmn42n/prescription_pain ) has ... Drugs - Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ ... Opportunities: 2015 - 2020 Analysis and Forecasts" ... is defined as an unpleasant sensory and emotional ... At some point, everyone experiences pain. Pain may ...
Breaking Medicine Technology:Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
... announced that the U.S. Food and Drug Administration ... treatment of adult patients with glioblastoma multiforme (GBM) ...  The portable, wearable device delivers an anti-mitotic, anti-cancer ... The NovoTTF is a novel, first-in-class treatment option ...
... 2011 StelKast is proud to announce the ... Acetabular Liners. EXp™, a blend of antioxidant and ... consulting support of Steven Kurtz, Ph.D. and Exponent, ... clearance for large diameter cobalt-chrome femoral heads and ...
Cached Medicine Technology:FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 2FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 3FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 4A Better Acetabular Solution from StelKast ... Naturally 2
(Date:8/31/2015)... ... August 31, 2015 , ... ... include a wealth of information for specific translation services within the medical and ... an incredible track record of successful work. , ITC Global Translations specializes in ...
(Date:8/31/2015)... ... August 31, 2015 , ... India Network Foundation, a ... ” tool, which summarizes all available plans, plan maximums, pre-existing condition coverage limits ... to help India Network members make an informed decision regarding the care they ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... classes. , Starting September 1st they are offering pre and postnatal ... and "Healthy Body, Healthy Baby." , More information can be found at 248-601-6683. ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Sundance Film Festival award ... September 1. , “Alive Inside” shadows a social worker who advocates for the use ... a documentary about bringing music to residents in health care centers who may have ...
(Date:8/31/2015)... Plains, NJ (PRWEB) , ... August 31, 2015 , ... ... high quality, patient-oriented dental care. From the moment a patient arrives at the ... and Steven Tuckman will work with each and every patient to create a complete ...
Breaking Medicine News(10 mins):Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2
... ... SecureWorks®, Inc., a leading global provider of information security services ... at its healthcare clients doubled in the fourth quarter of 2009. ... per day in the first nine months of 2009 to an ...
... evolution a field that often deals with changes over ... disease in our lifetime? A lot, some scientists say. If ... on evolution in medical entrance and licensing exams, says an ... articles in the January 26 issue of Proceedings of ...
... technique to catch cancer early has taken an important ... NPL,s ,phantoms, will ensure an exciting new screening technique ... signs of cancer. The technique, Optical Coherence Tomography ... the surface of certain materials, notably human tissue. It ...
... Improved delivery of end-of-life care in prison is the ... of Nursing Research that has Penn State researchers working ... Department of Corrections. The project will develop an intervention ... the country. End-of-life care -- an attempt to optimize ...
... 26, 2010 A Universit de Montral research team is ... our brain to stop eating. "Mice deprived of leptin will ... moving around," says Mose Bendayan, a pathology professor at the ... leptin protein extensively. Leptin regulates appetite in mammals and ...
... ... is on a mission to meet Matt Lauer when he is in Vancouver to shoot ... ... fruit bars ( www.elevateme.com ) is on a mission to meet Matt Lauer when he ...
Cached Medicine News:Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 2Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 3Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 4Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 5Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 6Health News:Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks' Data 7Health News:Medical students may soon be tested on evolution 2Health News:Medical students may soon be tested on evolution 3Health News:New measurement technique will help in fight against cancer 2Health News:End-of-life care strategies examined in Pennsylvania prisons 2Health News:A gimmick-free weight-loss pill in the works 2Health News:Vancouver Company Must Meet Matt Lauer During Olympics 2
9mm Curved Blades with Sharp Pointed Tips; overall length 90mm; Stainless Steel....
Straight shaft with fine pointed 0.3mm Tips for Grasping Delicate Capsule; In Titanium....
Smooth colibri tip; In Titanium....
45 Degree Angle With 0.3, 12 Teeth with 5mm Tying Platform; In Titanium....
Medicine Products: